The system showed activity on CD19 and GD2 models [19] and was later expanded to the AML targets CD33, CD38, CD123, CD135, and CD371 (CLL-1) [67], suggesting tuneable, multiplexed, and logic-gating strategies, though clinical validation is still lacking. The gene discussed is CD19; the disease is acute myeloid leukemia.